402 Serum cytokine profiling reveals elevated levels of S100A8/A9 and MMP-9 in systemic lupus erythematosus patients with cognitive impairment independently of disease activity and inflammatory markers. (14th December 2022)

• Record Type: Journal Article
• Authors: Grajales, Carolina Muñoz; Barraclough, Michelle L; Diaz-Martinez, Juan P; Su, Jiandong; Bingham, Kathleen; Kakvan, Mahta; Carmela Tartaglia, M; Ruttan, Lesley; Choi, May Y; Appenzeller, Simon; Bonilla, Dennisse; Katz, Patricia; Beaton, Dorcas; Green, Robin; Wither, Joan; Touma, Zahi
• Is Part Of: Lupus science & medicine. Volume 9(2022)Supplement 3
• Page Start: A12
• Page End: A14
• Publication Date: 2022-12-14
• Subjects: Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1136/lupus-2022-lupus21century.14
• Languages: English
• ISSNs: 2398-8851

Abstract

Abstract : Background: Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric lupus (NPSLE), which may occur in the absence of active Systemic Lupus Erythematosus (SLE) and negatively impacts patients' daily functioning and health-related quality of life. Therefore, identifying patients at high risk of developing CI is essential to prevent the accrual of damage and disability. However, its pathogenesis is largely unknown, and currently, biomarkers for the risk of CI are lacking. Here we investigated whether SLE patients with CI have elevated serum levels of cytokines that previous studies have suggested to have a potential pathogenic role in NPSLE. Methods: 291 individuals between 18-65 years old who met the 2019 EULAR/ACR classification criteria for SLE were included. Cognitive assessment was performed by a psychometrist and included the comprehensive 1-hour ACR Neuropsychological Battery (ACR-NB), which encompasses 19 cognitive tests representing six cognitive domains. The serum levels of nine cytokines (IL-10, IL-6, IFN-γ, TNF-α, TWEAK, MMP-9, S100 A8/A9, NGAL, and S100B) were determined using ELISA kits (R&D Systems). Differences in the serum levels of the cytokine profile between patients with and without CI (defined as a z-score of ≤-1.5 in two or more domains in the ACR-NB) were determined by the Mann-Whitney U test. Correlations were assessed using Spearman's rank correlation coefficient and the association of the different cytokine levels with each CI test score by logistic regression. Results: Forty percent of the patients (n=116) had CI. While no differences in the demographic characteristics and disease activity were observed between patients with and without CI, serum levels of S100A8/A9 and, to a lesser extent, MMP-9 were significantly higher in patients with CI (figure 1). When the ACR-NB's domains were examined individually, patients with impaired simple attention and processing; visual-spatial construction; learning and memory; or executive function also had significantly higher S100A8/A9 than those without impairment (figure 2). Indicative of probable collinearity, S100A8/A9 and MMP-9 moderately correlated with each other (Rho=0.52, p<0.0001) and both correlated with NGAL (Rho=0.64, p<0.0001; Rho=0.56, p< 0.0001, respectively). S100A8/A9 had the strongest relationship with multiple CI tests by logistic regression. The serum levels of S100A8/A9 and MMP-9 did not correlate with TNF-α, IL-6, hs- CRP, or disease activity as determined by the SLE Disease Activity Index-2000 (SLEDAI-2K). Conclusion: Among the multiple cytokines measured, only the heterodimer of the calcium- binding proteins S100A8 and S100A9 and MMP-9 were found to be increased in SLE patients with CI. The lack of correlation with the levels of other pro-inflammatory markers and its differential association with distinct cognitive domains may indicate that, in the setting of CI, S100A8/A9 mediates a regional neuroinflammatory response rather than systemic pro- inflammation. These results open new avenues to study the role of S100A8/A9 and MMP-9 in CI in adults with SLE.